ScaleReady

We’ve been eager to let you know about the rollout of a $20 million G-Rex Grant Program which goes live today and is accessible to every cell and gene therapy entity that is moving toward, or already conducting, clinical manufacturing. The program goal is to ensure that every recipient is able to establish the most cost effective manufacture of clinical products in the shortest amount of time. To meet that goal, the G-Rex Grant Program includes a wide range of essential products, services, and expertise that will all be made available to recipients. We hope that academic entities and private companies will take advantage of this program. It’s open to all, designed to be very easy to use, and we’re confident that every participant will find it highly beneficial. This program is possible thanks to the participation of forward-thinking collaborators who are dedicated to making a meaningful impact in the field of cell and gene therapy, including Wilson Wolf Manufacturing, LLC, Bio-Techne, CellReady™, Akadeum Life Sciences, Inc., MaxCyte, Inc., and Vector BioMed, Inc. If there are other like-minded entities that have the ability to help propel our goal, please don’t hesitate to reach out to us. We’d also kindly request that people seeing this message repost it so that it reaches the broadest audience possible. You can learn more about how easy it is to become a recipient of a G-Rex Grant here: https://lnkd.in/eWesmsWJ #cellandgenetherapy #GRex #innovation #collaboration

It's our great pleasure to support CuraCell through the G-Rex Grant Program and to bring hope to metastatic prostrate and colorectal cancer patients through their innovative TIL Therapy. #cellandgenetherapy

Ignacio Núñez, COO of CellReady™, talks to IBTV about streamlining CGT operations utilizing the proven methodologies and frameworks that have pushed other industries forward, faster. Check out the interview from Advanced Therapies Terrapin below >>> #CGT #LeanManufacturing #ProcessDevelopment #CellTherapyManufacturing

What do investors look for in cell therapy companies? Ignacio Núñez breaks it down: >Strong scientific concepts and value-driven technology. >The ability to 'fail fast' and generate data quickly. >A seamless manufacturing platform from preclinical to commercial. These three traits can transform a company into a 'very sexy asset' for investors. 📈 Curious how your company stacks up? Watch the full video and dive into the details. What strategies are you using to stand out? ScaleReady CellReady™ #CellTherapy #Biotech #Investment #FailFast #Innovation

Discover how ScaleReady's Global Commercial Director, Josh Ludwig, envisions the future of cell and gene therapy manufacturing in the latest Drug Discovery World article. He emphasizes the critical need for simple, scalable, and cost-effective processes to unlock the full potential of these therapies in healthcare. Read the full article here>>>> https://lnkd.in/eykAj9q5 #CellTherapy #GeneTherapy #BiotechInnovation #HealthcareTransformation #ScalableManufacturing

At the forefront of cell and gene therapy, we're proud to continue leading open collaboration among tool and technology providers. Our mission is simple: empower therapy developers with the best-in-class technologies for a streamlined, modular workflow. "Open collaboration is critical," says Josh Ludwig, our Global Commercial Director in this interview with IBTV. We're thrilled to showcase innovations in partnerships like our Applied Cells MARS Bar and customized ThermoFisher incubators, all designed to boost high -throughput potential. Join us as we set new standards in the industry! #CellTherapy #GeneTherapy #Innovation #Biotech #Collaboration

What if we told you that the future of engineered human skin doesn’t need an air-liquid interface (ALI) to stratify correctly? Thanks to the clever use of G-Rex® by researchers at the @ University of Auckland, keratinocytes grown at a gas-permeable interface (GPI) have achieved full epidermal stratification without the traditional ALI approach—and the benefits are game-changing. Why is G-Rex a breakthrough for skin engineering? --Less time and labor ⏳ – Traditional ALI methods require constant liquid-level adjustments, but G-Rex eliminates this need by maintaining a steady culture environment. --Lower contamination risks 🦠 – G-Rex’s closed-system design minimizes handling steps, reducing sterility concerns. --Scalability and automation 🔄 – With G-Rex's high-volume culture capacity, larger skin grafts can be produced more efficiently. --Cost efficiency 💰 – By reducing reliance on highly skilled personnel for maintenance, G-Rex significantly cuts production costs.   G-Rex successfully triggered keratinocyte differentiation, forming all layers of the epidermis, including a fully developed Stratum Corneum, and maintaining key markers of epidermal function, such as Cytokeratin 10, Cytokeratin 14, Filaggrin, and Loricrin, proving its clinical viability. The publication illustrates a major breakthrough for wound care where G-Rex could streamline in vitro skin graft production and reduce barriers to clinical application, including burn treatment and regenerative medicine, by enabling faster, more scalable, and reduced contamination risk skin graft production.   Read the full publication here --> https://lnkd.in/eVPd8zHQ   Shoutout to the brilliant team behind this research! Vaughan Feisst, Lisa Zhou, Chun-Jen Jennifer Chen, Eloise Williams, Elliott Dunn, Inken Kelch, Sarah Meidinger, John M.T. Hunt, Alex du Rand, Heidi Robinson, Saem M. Park, Evert J. Loef, Julian Lofts, Hilary Sheppard, Michelle Locke, P. Rod Dunbar, Maurice Wilkins Centre St Marks Road Surgical Centre, CountiesManukau District Health Board #RegenerativeMedicine #CellTherapy #GeneTherapy #TissueEngineering #WoundCare #BurnTreatment #StemCells #Biotechnology #MedTech #ScaleReady #GRexTechnology

ScaleReady is a proud sponsor of the Alliance for Cancer Gene Therapy's Annual Summit. Barbara Lavery did a phenomenal job developing an action-packed agenda with world-class #cellandgenetherapy leaders. Day 1 got off to a great start with speakers from Regeneron, Bristol Myers Squibb, AstraZeneca, and Medici Therapeutics on the keynote panel talking about Pharma's current perspective on the CGT. Despite a lot of the noise, the future for CGT is bright! #ACGT25

Scaling cell and gene therapies isn’t just a technical challenge—it’s a strategic one. Ignacio Núñez breaks down how process mapping and waste elimination can unlock real efficiency in CGT manufacturing. 💡 Key Takeaways from Ignacio Núñez: ✔ “You can’t scale what you don’t measure.” – Data-driven decision-making is critical for efficiency. ✔ “Waste in manufacturing isn’t just about cost—it’s about patient access.” – Faster processes mean faster treatments. ✔ Lean & Six Sigma aren’t just buzzwords—they are practical tools that can revolutionize how therapies are produced. Learn more about Lean Manufacturing in CGT this week at #AdvancedTherapiesWeek2025 in London as Ignacio takes the stage at 1:20pm this Tuesday! 🔥 What’s the biggest bottleneck in CGT manufacturing today? Drop your thoughts below! Watch the full discussion with Ignacio Núñez and join the conversation! 🔗 #CGT #CellTherapyManufacturing #ProcessOptimization #Biopharma #LeanSixSigma